IC inhibitors (ICIs), i.e., antibodies targeting CTLA-4, PD-1, or PD-L1, are used as immunomodulatory agents to interfere with the CTLA-4:B7-1/2 or PD-1:PD-L1 axes and to help to overcome tumor-immune escape [24,25,26] with very different efficacy. Here, CTLA4 is linked to neoplasm.